Alumis
Ruixiao Lu has a diverse work experience spanning multiple companies and roles. Currently, they are the VP and Head of Biostatistics and Statistical Programming at Alumis, a precision medicine company focused on autoimmune diseases. They have also held leadership positions at various organizations such as the Bay Area Biotech-Pharma Statistics Workshop (BBSW) and the American Statistical Association (ASA). In addition, they have co-founded a non-profit organization called DahShu and have worked in the biostatistics field at companies like Quantum Leap Healthcare Collaborative, Exact Sciences, Genomic Health, Novartis, Affymetrix, and Tethys Bioscience, Inc. Throughout their career, Ruixiao has demonstrated their expertise in statistical analysis, team management, and strategic leadership.
Ruixiao Lu obtained a Bachelor's degree in Statistics from Peking University, School of Mathematical Sciences, from 1999 to 2003. They went on to pursue a PhD in Statistics (with an emphasis in Biostatistics) from the University of California, Davis, completing their studies from 2003 to 2007.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.